How to appeal an Aetna substance use disorder treatment (sud/moud) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for substance use disorder treatment (sud/moud)

Cited policy: Aetna Clinical Policy Bulletin (SUD Treatment) + Aetna Clinical Policy Bulletin (Buprenorphine for OUD)

DSM-5 SUD diagnosis. CPB criteria for LOC. ASAM-aligned in CA / parity states.

How Aetna denies substance use disorder treatment (sud/moud) — and how to counter it

Where Aetna pushes back: 1) Buprenorphine dose >24 mg denied as 'exceeds FDA labeling'; 2) Concurrent bupe + benzo flagged contraindicated; 3) Residential denied per CPB 0584 LOC criteria.

Counter-arguments that hold up: FDA Drug Safety Communication 2017 — bupe + benzo should NOT be withheld when clinically indicated; black-box walked back for OUD. Doses >24 mg supported by SAMHSA TIP 63 for high-tolerance / fentanyl-era patients (up to 32 mg). ASAM 4e LOC determination overrides Aetna internal criteria where state law (CA SB 855, NY) mandates GASC. DATA 2000 removal — no specialist gatekeeping permissible.

What Aetna typically denies for substance use disorder treatment (sud/moud)

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For substance use disorder treatment (sud/moud), expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the substance use disorder treatment (sud/moud) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Suboxone (subli)
• Sublocade LA
• Brixadi LA
• Methadone OTP
• Vivitrol LA
• Naltrexone PO

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.